Hello! Welcome to the official website of Betta Pharmaceuticals!
Helpline:0571-86130357     Add to Favorites | Online Feedback 中文
Ding Lieming
Ding Lieming
Chairman of the board, CEO and Doctor of Medicine.

Ding Lieming: Chairman of the board, CEO and Doctor of Medicine. Deputy of the 12th National People’ Congress, U.S. practitioner in Pathology, practice mentor of Zhejiang University, enjoys the State Council special allowance; Graduated from the Medical School of University of Arkansas; Returned to China at the end of 2002 and founded Zhejiang Betta Pharmaceuticals Co., Ltd. Selected to be a member of the national “Recruitment Program of Global Experts” in 2009; winner of the Overseas Chinese Community Creative Talent Award in 2010; winner of the Outstanding Contribution Award for implementing “The 11th Five-Year Plan” National Science and Technology Plan in 2011; elected as the leader of the innovative drug development and industrialization working group of the national “Recruitment Program of Global Experts” Association and the managing director of Chinese Pharmaceutical Association and won the Overseas Chinese Community Innovation Team Contribution Award in 2012; winner of the 3rd Outstanding Talent Award of Hangzhou in 2013; winner of the title of “The 5th National Outstanding Professional and Technical Talent”, “The 2014 Innovation Role Model of China” award, and elected as the 10th vice-chairman of China Pharmaceutical Industry Research and Development Association in 2014 ; 


Wang Yinxiang
Wang Yinxiang
President/Chief Scientist

Wang Yinxiang: President/Chief Scientist, PhD, successively engaged in postdoctoral research in molecular biophysics and biochemistry at Yale University, returned to China in 2003 and founded the Beijing Innovative Drug R&D Center of Betta Pharmaceuticals. Served concurrently as a distinguished professor for the New Drug Safety Assessment Center of Chinese Academyof Medical Sciences. Served as a distinguished professor for the New Drug Safety Assessment Center of Peking Union Medical College, ChineseAcademy of Medical Sciences in 2006. Selected to be a member of the New Century “131” Outstanding Young and Middle-Aged Talents Training Plan of Hangzhou in 2007; winner of the special allowance of Hangzhou in 2010; selected to be a member of “Hangzhou ‘521 Recruitment Program’ of Global Talents” in 2011; rated as high-quality overseas professionals of new districts of Beijing in 2011; selected to be a member of the national “Recruitment Program of Global Experts” in 2012.

Tan Fenlai
Tan Fenlai
Vice-President/Chief Medical Officer

Tan Fenlai: Vice-President/Chief Medical Officer, PhD, graduated from the Medical School of Arkansas State University. Successively engaged in postdoctoral research at Cleveland Clinic and the Medical School of the Universityof Michigan. Returned to China in 2007 and began serving as the director of the Innovative drug R&D center, where he was in charge of R&D and clinical research of the company. Member of American Society of Clinical Oncology (ASCO) and American Diabetes Association (ADA). Selected to be a member of the New Century “131” Outstanding Young and Middle-Aged Talents Training Plan of Hangzhou in 2008; Selected to be a member of the “Recruitment Program of High-Quality Overseas Professionals” (Recruitment Program of Global Experts) of Zhejiang Province and served as one of the first group of “Distinguished Experts” of Hangzhou in 2010; selected to be a member of the national “Recruitment Program of Global Experts” in 2012.

Hu Shaojing
Hu Shaojing
Chief Chemist

Hu Shaojing: Chief Chemist, PhD, earned a doctoral degree from Simon Fraser University inCanada. Engaged in postdoctoral research at YaleUniversity. Successively served as the chief researcher of Institute for Diabetes Discovery and Neurogen. 15 years of experiences in development of tumor, obesity, diabetes, nervous centralis and anti-inflammatory new drugs. Head of the Innovative Drug Development and Intellectual Property Department of the company. Hired as a distinguished expert by Hangzhou Qianjiang Economic Development Area; selected to be a member of the national “Recruitment Program of Global Experts” in 2012.

Zhu Lingyu
Zhu Lingyu
Vice-Strategic Cooperation President

Zhu Lingyu: Vice-Strategic Cooperation President, graduated as a Biochemistry Ph.D. from Ohio StateUniversity and MBA from Michigan Ross School of Business. Successively served as business development manager, business development director for big pharmaceutical companies including Esperion Therapeutics, Johnson & Johnson, Pfizer, Xian-Janssen Pharmaceutical Ltd. and so forth. Elected as high-quality overseas professional by Beijing Economic Technological Development Area in 2012. Currently in charge of project introduction, business cooperation as well as technology transfer of the company. Selected to be a member of the “Recruitment Program of Global Experts” of Yuhang District.